Cleo Diagnostics Ltd Total Assets
Cleo Diagnostics Ltd total assets. Based on the latest financial reports, Cleo Diagnostics Ltd (COV) holds total assets worth AU$9.96 Million AUD (≈ $7.05 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Cleo Diagnostics Ltd (COV) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Cleo Diagnostics Ltd (2022–2025)
Total assets of Cleo Diagnostics Ltd from 2022 to 2025. This chart illustrates how Cleo Diagnostics Ltd's total assets have evolved over time, based on quarterly financial data. See Cleo Diagnostics Ltd share price for real-time trading data and today's change.
Cleo Diagnostics Ltd - Asset Composition Analysis
Cleo Diagnostics Ltd Total Assets Breakdown (June 2025)
Cleo Diagnostics Ltd total assets breakdown as of June 2025. Cleo Diagnostics Ltd's total assets of AU$9.96 Million consist of 94.4% current assets and 5.6% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$5.71 Million | 10.8% |
| Accounts Receivable | AU$70.57K | 1.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$32.59K | 0.5% |
| Intangible Assets | AU$358.33K | 5.2% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Cleo Diagnostics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Cleo Diagnostics Ltd (COV) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cleo Diagnostics Ltd's current assets represent 94.4% of total assets in 2025, an increase from 17.9% in 2022.
- Cash Position: Cash and equivalents constituted 10.8% of total assets in 2025, down from 17.6% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 82.0% in 2022.
- Asset Diversification: The largest asset category is cash and equivalents at 10.8% of total assets.
Cleo Diagnostics Ltd Competitors by Total Assets
Key competitors of Cleo Diagnostics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Vitrolife AB
ST:VITR
|
Sweden | Skr11.30 Billion |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.02 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Cleo Diagnostics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.46 | 16.70 | 51.69 |
| Quick Ratio | 8.46 | 16.70 | 51.69 |
| Cash Ratio | 8.30 | 16.32 | 0.00 |
| Working Capital | AU$8.46 Million | AU$7.03 Million | AU$10.07 Million |
Cleo Diagnostics Ltd - Advanced Valuation Insights
This section examines the relationship between Cleo Diagnostics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.99 |
| Latest Market Cap to Assets Ratio | 3.98 |
| Asset Growth Rate (YoY) | -29.8% |
| Total Assets | AU$6.94 Million |
| Market Capitalization | $27.60 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cleo Diagnostics Ltd's assets at a significant premium (3.98x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cleo Diagnostics Ltd's assets decreased by 29.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cleo Diagnostics Ltd (2022–2025)
The table below shows the annual total assets of Cleo Diagnostics Ltd from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$6.94 Million ≈ $4.91 Million |
-29.78% |
| 2024-06-30 | AU$9.88 Million ≈ $6.99 Million |
+817.52% |
| 2023-06-30 | AU$1.08 Million ≈ $761.78K |
+341.95% |
| 2022-06-30 | AU$243.61K ≈ $172.37K |
-- |
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing int… Read more